Timothy Chiang
Stock Analyst at Capital One
(0.16)
# 3,464
Out of 4,583 analysts
6
Total ratings
16.67%
Success rate
-12.75%
Average return
Main Sectors:
Stocks Rated by Timothy Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Initiates: Overweight | n/a | $61.05 | - | 1 | Mar 15, 2024 | |
| AKYA Akoya Biosciences | Initiates: Overweight | $19 | $2.84 | +569.01% | 1 | Nov 3, 2022 | |
| PTGX Protagonist Therapeutics | Initiates: Buy | $55 | $44.77 | +22.85% | 2 | Feb 11, 2022 | |
| AMPH Amphastar Pharmaceuticals | Upgrades: Outperform | n/a | $49.78 | - | 1 | Oct 5, 2020 | |
| IDYA IDEAYA Biosciences | Initiates: Outperform | $28 | $34.75 | -19.42% | 1 | Sep 1, 2020 |
ANI Pharmaceuticals
Mar 15, 2024
Initiates: Overweight
Price Target: n/a
Current: $61.05
Upside: -
Akoya Biosciences
Nov 3, 2022
Initiates: Overweight
Price Target: $19
Current: $2.84
Upside: +569.01%
Protagonist Therapeutics
Feb 11, 2022
Initiates: Buy
Price Target: $55
Current: $44.77
Upside: +22.85%
Amphastar Pharmaceuticals
Oct 5, 2020
Upgrades: Outperform
Price Target: n/a
Current: $49.78
Upside: -
IDEAYA Biosciences
Sep 1, 2020
Initiates: Outperform
Price Target: $28
Current: $34.75
Upside: -19.42%